Caladrius Biosciences Inc CLBS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:13 PM EST
1.88quote price arrow up+0.02 (+1.08%)
Volume
25,626
Close
1.86quote price arrow down-0.06 (-3.12%)
Volume
1,937,108
52 week range
1.05 - 4.89

...

Loading . . .

KEY STATS

  • Open1.92
  • Day High2.02
  • Day Low1.86
  • Prev Close1.92
  • 52 Week High4.89
  • 52 Week High Date01/20/21
  • 52 Week Low1.05
  • 52 Week Low Date03/19/20
  • Market Cap108.68M
  • Shares Out58.43M
  • 10 Day Average Volume8.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • 1 Year % Change-21.19

RATIOS/PROFITABILITY

  • EPS (TTM)-0.64
  • P/E (TTM)-2.91
  • Fwd P/E (NTM)-3.70
  • EBITDA (MRQ)-18.72M
  • ROE (MRQ)-24.37%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)9.15%
  • Net Margin (MRQ)-179.78%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Caladrius Biosciences Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification...
Gregory Brown M.D.
Chairman
David Mazzo Ph.D.
President
Address
110 Allen Rd
Basking Ridge, NJ
07920-4500
United States